Newly discovered proteins could help palaeontologists to investigate the behaviour, diet and evolution of animals long thought too old to be studied with molecular tools https://t.co/g7TWLHW1qf ...

There are tantalising hints that scientists might have even older proteins to discover. It could be a game changer for palaeontology https://t.co/tCA1eJaj5D ...

Until recently the oldest proteins recovered for reliable, in-depth analysis were around 4m years old. But now, two separate studies have discovered ancient ones some of which could be as old as 29m years https://t.co/9Smb5IZ3Be ...

Scientific Discovery - New discoveries expand the timeline of proteins available for analysis ten-fold compared to DNA [1] - Palaeontologists can now understand organisms that are too old for other ancient molecular analysis [1]

[Applause] [Applause] Thank you very much. Yes, I'm Ralph. Happy to be here and for me from my background here with medical science so to see my PhD I wrote in medical science but as mentioned working in shipping and logistics in pharmaceutical research and so on different kinds of fields also in business and that's why for me it's so important today for you to connect here the dots between molecules and corporate boardrooms how we work in the future.So that means how alpha fold is redefining leadership and ...

Corporate Presentation June 2025 JENNIFER Living with SCA3 JENNIFER Living with SCA3 Participant in the Troriluzole Clinical Study © 2025 Biohaven, Ltd. All rights reserved. Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Biohaven Ltd. (the "Company") and our planned and ongoing trials for our troriluzole, taldefgrobep alfa, BHV-7000, BHV-2100, BHV-8000, BHV-1300, BHV-1400, ...

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...

Summary of Rapport Therapeutics Investor and Analyst Day Company Overview - **Company**: Rapport Therapeutics - **Event**: Inaugural Investor and Analyst Day - **Focus**: Lead candidate RAP-two 19 for epilepsy treatment Key Points and Arguments Industry and Product Focus - **Lead Candidate**: RAP-two 19, a TARP gamma eight AMPA modulator, aimed at treating focal onset seizures in epilepsy [3][19] - **Market Size**: Focal epilepsy affects approximately 1.8 million patients in the U.S., with 30-40% being drug-resistant [32] - **Pipeline**: Fully enabled pipeline including RAP-two 19 and two late-stage discovery programs targeting chronic pain and hearing disorders [19][27] Clinical Trials and Results - **Phase Two Trial**: Ongoing trial for RAP-two 19 in focal onset seizure patients, fully enrolled with results expected in September [21][26] - **Phase One Results**: Completed four Phase I studies with 100 healthy volunteers; RAP-two 19 was safe and well-tolerated [52][53] - **Receptor Occupancy**: Achieved target receptor occupancy of 50-70% at lower doses than predicted, indicating potential for effective treatment [56][58] Scientific Insights - **Mechanism of Action**: RAP-two 19 selectively modulates AMPA receptors in specific brain regions, potentially reducing side effects associated with traditional anti-seizure medications [38][39] - **Preclinical Efficacy**: Demonstrated significant efficacy in animal models with a favorable safety profile compared to existing treatments [44][46] Management and Strategy - **Management Team**: Comprised of experienced professionals in neuroscience and drug development, emphasizing a strategic approach to building the company [15][17] - **Vision**: To create a leading precision neuroscience company, addressing the limitations of conventional small molecules in treating neurological disorders [24][25] Additional Important Content - **Unmet Needs**: Despite numerous treatment options, the number of treatment-resistant epilepsy patients remains unchanged, highlighting the need for innovative therapies [92][93] - **Patient Population**: The trial population is representative of refractory focal epilepsy patients, enhancing the translatability of results to broader populations [87] - **Long-Acting Injectable**: Potential development of a long-acting injectable formulation for RAP-two 19, which could transform treatment for epilepsy patients [29][30] Conclusion Rapport Therapeutics is positioned to address significant unmet needs in the epilepsy treatment landscape with its innovative lead candidate RAP-two 19, backed by a robust clinical and scientific foundation. The company's strategic focus on precision neuroscience and the experienced management team further enhance its potential for success in the market.

Core Viewpoint - Dyadic International, Inc. is undergoing a strategic shift to become a revenue-generating provider of ancillary recombinant protein products, with a focus on life sciences, nutrition, and industrial markets [1][2][3] Group 1: Leadership Changes - Joe Hazelton has been appointed as President, effective immediately, while continuing as Chief Operating Officer [1][6] - The leadership change aims to align the company’s focus on accelerating growth in the ancillary protein space [3][4] Group 2: Strategic Shift and Market Focus - Over the past 18 months, Dyadic has prioritized commercialization opportunities in high-growth segments such as cell culture media and non-animal food ingredients [2][8] - The company has achieved commercial validation through partnerships, including a collaboration with Proliant Health for recombinant human albumin and a joint venture with Fermbox Bio [2][4] Group 3: Operational and Strategic Goals - Joe Hazelton will oversee scaling scientific and commercial initiatives, deepening industry partnerships, and guiding corporate rebranding efforts [3][4] - The company’s C1 and Dapibus™ platforms are central to its strategy, enabling large-scale production of recombinant proteins for non-therapeutic applications [4][9] Group 4: Legacy Programs - While focusing on ancillary proteins, Dyadic will continue to develop its legacy biopharmaceutical programs under the oversight of Mark Emalfarb [5]

LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Ba ...